NASDAQ: LKFTLakefront Biotherapeutics Nv Stock
$28.11+0.60 (+2.18%)
Updated Jun 4, 2026
LKFT Price
$28.11
Fair Value Price
N/A
Market Cap
$1.85B
52 Week Low
$26.42
52 Week High
$37.78
P/E
N/A
P/B
0.48x
P/S
1.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.16B
Earnings
$561.81M
Gross Margin
97.9%
Operating Margin
47.97%
Profit Margin
49.7%
Debt to Equity
0.04
Operating Cash Flow
-$413M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LKFT Overview
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LKFT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LKFT
Ranked#100 of 466
Ranked#100 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $240.06 | A | |
| $6.15 | A | |
| $279.93 | A |
Be the first to know about important LKFT news, forecast changes, insider trades & much more!
LKFT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LKFT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LKFT is good value based on its book value relative to its share price (0.48x), compared to the US Biotechnology industry average (4.84x)
P/B vs Industry Valuation
LKFT's cash and short-term investments ($3.51B) can cover LKFT's cash burn for the next year (N/A), after accounting for decreasing cash burn (N/A)
Interest Coverage Financials
LKFT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more LKFT due diligence checks available for Premium users.
Valuation
LKFT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
18.35x
Market
23.52x
LKFT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
4.84x
LKFT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LKFT's financial health
Profit margin
Revenue
$9.3M
Net Income
$16.7M
Profit Margin
179.9%
LKFT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LKFT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.9B
Liabilities
$136.9M
Debt to equity
0.04
LKFT's short-term assets ($3.60B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LKFT's short-term assets ($3.60B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LKFT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$108.7M
Investing
$70.7M
Financing
-$586.2k
LKFT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LKFT vs Biotech Stocks
Lakefront Biotherapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.